We are thrilled to announce the recent promotions of our dedicated Halloranites 🎉 Your hard work and commitment have truly paid off. Congratulations to each of you—we celebrate your achievements today! Cheers to you Bridget Hindman, Alex Makowitz, Genna Jenkins, Krista Tibbs, Meghan Patterson, & Shawn Roach! #feelgoodfriday #promotions #companyculture #damngoodconsulting
Halloran Consulting Group, Inc.
Business Consulting and Services
Boston, Massachusetts 7,365 followers
Halloran is a life science consulting firm providing strategic regulatory, quality, and clinical insights.
About us
Halloran Consulting Group is a life science consulting firm that provides strategic regulatory, quality, clinical, and organizational support to industry leaders and startup visionaries in the pharmaceutical, biotechnology, and medical device sectors. Our consultants are subject matter experts who deliver a tailored approach to each engagement, successfully propelling our clients to their next inflection point. We connect clients with our trusted industry partners to drive operational excellence and innovation throughout their organizations. Our aim is to support our clients, and the patients they serve.
- Website
-
http://www.hallorancg.com
External link for Halloran Consulting Group, Inc.
- Industry
- Business Consulting and Services
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 1998
- Specialties
- Regulatory Strategy/Submissions, Quality Systems, Clinical Development, Due Diligence, TMF, Organizational Development, Program Management, Gap Analysis, Clinical Finance, Change Management, Vendor Management, Inspection Readiness, Training, Technology Adoption, Clinical Trials, Clinical Research, Virtual Clinical Trials, Decentralized Clinical Trials, Organizational Solutions, Data Management, Technology Implementation, Strategy Management, and Program Leadership
Locations
-
Primary
22 Thomson Pl
Boston, Massachusetts 02210, US
-
3040 Science Park Rd
San Diego, California 92121, US
Employees at Halloran Consulting Group, Inc.
Updates
-
Tools like #AI offer numerous benefits for life science product development companies, but that optimism must be balanced with practical caution. During a #DIA2024 session, we learned about the positive use case of AI in medical writing, however, we must remember that human intervention is necessary. https://hubs.la/Q02GbBq60 Read Gail Winslow, MS, APR translation. Need to discuss your medical writing needs? Contact us. #ClinicalDevelopment #MedicalWriting #ArtificialIntelligence
-
After #DIA2024 wrapped, April Purcell and Michelle Peter sat down with Gail Winslow, MS, APR to share their experience and lessons learned for sponsor companies. Curious? Read their Q&A: https://hubs.la/Q02G46B80 #IndustryInsights #Innovation #ClinicalDevelopment
Catching Up with Consulting — DIA 2024 Insights | Halloran Consulting Group
https://www.hallorancg.com
-
The #DIA2024 session “The State of Clinical Trials in 2024: Are We Making the Grade?” emphasized clinical trials are generating unprecedented amounts of data, raising questions about which data to prioritize and how to derive meaningful insights. Read Gail Winslow’s session translation. Halloran’s data integrity service prepares your organization for evolving regulatory requirements impacting data integrity by implementing scalable data oversight processes, procedures, and governance. Our training programs aim to ensure your teams are equipped with the latest industry knowledge to strengthen your organization’s ability to handle the data deluge. https://hubs.ly/Q02FVFs60 #clinicalresearch #clinicaldata #dataintegrity #gxp
Clinical Trials in 2024 -- Are We Making the Grade? | Halloran Consulting Group
https://www.hallorancg.com
-
Join us for our webinar, "Your Regulatory CMC Roadmap: Clinical Development Considerations for Small Molecules and Recombinant Proteins," on August 1st from 12 - 1 PM EST. Our experts, Shawn Roach, Rania Jalal, Ph.D., and Rosalind Hafen, will cover critical priorities for clinical development, differences in CMC strategies, common pitfalls, and more. Don't miss this opportunity to enhance your Regulatory CMC knowledge. 👉 Register now: https://hubs.la/Q02FHZDv0 #Biotech #Pharma #CMC #Webinar #ClinicalDevelopment #RegulatoryAffairs
-
This Independence Day, we celebrate the innovation, perseverance, and spirit that has helped shape this nation. We hope you all have a spark-tacular and a safe holiday! #4thofJuly #IndependenceDay
-
Before the Orphan Drug Act (ODA) was signed into law, the FDA approved approximately two drugs per year for rare diseases. Now, 40 years after the ODA, hundreds of orphan drugs have been approved for use in the many diseases and conditions that are considered rare. What’s in store for the next 40 years? Read Gail Winslow, MS, APR take on insights shared during the panel, “Sustainability of Rare Disease Drug Development,” at #DIA2024 https://hubs.la/Q02F7rN60 #orphandisease #raredisease #orphandrugact #FDA #acceleratedapproval
The Next 40 Years of the Orphan Drug Act
https://www.hallorancg.com
-
Join Consulting Magazine for an insightful panel discussion featuring Halloran's COO, Brittany Sipos, where operational leaders from professional services firms will delve into the importance of agility, flexibility, and efficiency in driving innovation and growth. Discover how these qualities enhance creativity, productivity, and expertise, beyond just cutting costs. Don't miss this opportunity to gain valuable insights from a recent C-level survey and learn about innovative strategies that elevate performance in professional services. 📅 Thursday, July 11, 2024 | 11am EST 🔗 https://hubs.la/Q02CKtwj0 #ProfessionalServices #Innovation #OperationalEfficiency #Technology #AI
Balancing Growth Objectives with Operational Efficiency: Unleashing Partner Productivity
consultingmag.com
-
Last year, the FDA released, “A Risk-Based Approach to Monitoring of Clinical Investigations, Questions and Answers, Guidance for Industry.” This guidance is noted to expand on the prior guidance released over a decade ago. Our team has seen an interest from our life science community in our review of the guidance’s four key themes: questions concerning risk, developing your monitoring strategy, risk assessment as a continuous process, and the importance of a root cause analysis. https://hubs.la/Q02CDJsg0 If you are interested in further unpacking this guidance or have questions about your monitoring approach, we’re ready to start the conversation. #FDAGuidance #ClinicalTrials #ClinicalInvestigations #RiskBasedMonitoring #QMS #QualityManagement
Risk-Based Approach to Monitoring of Clinical Investigations
https://www.hallorancg.com
-
Halloran is #hiring! Join our team! Click here to discover our available positions: https://hubs.la/Q02CKvcf0 #SalesJobs #ConsultingJobs #LifeScienceJobs #RegulatoryJobs